Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2008, Article ID 147905, 8 pages
http://dx.doi.org/10.1155/2008/147905
Research Article

Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correlation Analysis

1Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
2Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

Received 31 December 2007; Accepted 23 August 2008

Academic Editor: Paolo Vineis

Copyright © 2008 Zhibin Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. B. Thompson, “Apoptosis in the pathogenesis and treatment of disease,” Science, vol. 267, no. 5203, pp. 1456–1462, 1995. View at Publisher · View at Google Scholar
  2. G. I. Evan and K. H. Vousden, “Proliferation, cell cycle and apoptosis in cancer,” Nature, vol. 411, no. 6835, pp. 342–348, 2001. View at Publisher · View at Google Scholar
  3. S. W. Lowe and A. W. Lin, “Apoptosis in cancer,” Carcinogenesis, vol. 21, no. 3, pp. 485–495, 2000. View at Publisher · View at Google Scholar
  4. I. M. Ghobrial, T. E. Witzig, and A. A. Adjei, “Targeting apoptosis pathways in cancer therapy,” CA-A Cancer Journal for Clinicians, vol. 55, no. 3, pp. 178–194, 2005. View at Publisher · View at Google Scholar
  5. D. H. Phillips, “Fifty years of benzo(a)pyrene,” Nature, vol. 303, no. 5917, pp. 468–472, 1983. View at Publisher · View at Google Scholar
  6. H. V. Gelboin, “Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes,” Physiological Reviews, vol. 60, no. 4, pp. 1107–1166, 1980. View at Google Scholar
  7. M. C. MacLeod and M. Tang, “Interactions of benzo(a)pyrene diol-epoxides with linear and supercoiled DNA,” Cancer Research, vol. 45, no. 1, pp. 51–56, 1985. View at Google Scholar
  8. C.-B. Ko, S.-J. Kim, C. Park et al., “Benzo(a)pyrene-induced apoptotic death of mouse hepatoma Hepa1c1c7 cells via activation of intrinsic caspase cascade and mitochondrial dysfunction,” Toxicology, vol. 199, no. 1, pp. 35–46, 2004. View at Publisher · View at Google Scholar
  9. W. Lei, R. Yu, S. Mandlekar, and A.-N. T. Kong, “Induction of apoptosis and activation of interleukin 1β-converting enzyme/ced-3 protease (caspase-3) and c-Jun NH2-terminal kinase 1 by benzo(a)pyrene,” Cancer Research, vol. 58, no. 10, pp. 2102–2106, 1998. View at Google Scholar
  10. M. Ramet, K. Castren, K. Jarvinen et al., “p53 Protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines,” Carcinogenesis, vol. 16, no. 9, pp. 2117–2124, 1995. View at Publisher · View at Google Scholar
  11. T. Miyashita and J. C. Reed, “Tumor suppressor p53 is a direct transcriptional activator of the human bax gene,” Cell, vol. 80, no. 2, pp. 293–299, 1995. View at Publisher · View at Google Scholar
  12. M. Bennett, K. Macdonald, S.-W. Chan, J. P. Luzio, R. Simari, and P. Weissberg, “Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis,” Science, vol. 282, no. 5387, pp. 290–293, 1998. View at Publisher · View at Google Scholar
  13. M. S. Sheikh, T. F. Burns, Y. Huang et al., “p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor a,” Cancer Research, vol. 58, no. 8, pp. 1593–1598, 1998. View at Google Scholar
  14. D. R. Green and G. Kroemer, “The pathophysiology of mitochondrial cell death,” Science, vol. 305, no. 5684, pp. 626–629, 2004. View at Publisher · View at Google Scholar
  15. A. Ashkenazi and V. M. Dixit, “Death receptors: signaling and modulation,” Science, vol. 281, no. 5381, pp. 1305–1308, 1998. View at Publisher · View at Google Scholar
  16. S. W. Lowe, E. Cepero, and G. Evan, “Intrinsic tumour suppression,” Nature, vol. 432, no. 7015, pp. 307–315, 2004. View at Publisher · View at Google Scholar
  17. Q. Wei, L. Cheng, C. I. Amos et al., “Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study,” Journal of the National Cancer Institute, vol. 92, no. 21, pp. 1764–1772, 2000. View at Publisher · View at Google Scholar
  18. X. Wu, H. Zhao, C. I. Amos et al., “p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity,” Journal of the National Cancer Institute, vol. 94, no. 9, pp. 681–690, 2002. View at Google Scholar
  19. B. L. Park, L. H. Kim, H. S. Cheong et al., “Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2),” Journal of Human Genetics, vol. 49, no. 8, pp. 449–454, 2004. View at Publisher · View at Google Scholar
  20. A. Saxena, O. Moshynska, K. Sankaran, S. Viswanathan, and D. P. Sheridan, “Association of a novel single nucleotide polymorphism, G(-248)A, in the 5-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance,” Cancer Letters, vol. 187, no. 1-2, pp. 199–205, 2002. View at Publisher · View at Google Scholar
  21. G. MacPherson, C. S. Healey, M. D. Teare et al., “Association of a common variant of the CASP8 gene with reduced risk of breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 24, pp. 1866–1869, 2004. View at Publisher · View at Google Scholar
  22. A. Hirano, H. Nagai, H. Harada, S. Haga, T. Kajiwara, and M. Emi, “Two novel single-nucleotide polymorphisms of the Caspase-9 (CASP9) gene in the Japanese population,” Genes and Immunity, vol. 2, no. 2, pp. 117–118, 2001. View at Publisher · View at Google Scholar
  23. M. J. Fisher, A. K. Virmani, L. Wu et al., “Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer,” Clinical Cancer Research, vol. 7, no. 6, pp. 1688–1697, 2001. View at Google Scholar
  24. Q. R. Huang, D. Morris, and N. Manolios, “Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene,” Molecular Immunology, vol. 34, no. 8-9, pp. 577–582, 1997. View at Publisher · View at Google Scholar
  25. J. Wu, C. Metz, X. Xu et al., “A novel polymorphic CAAT/enhancer-binding protein ß element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients,” Journal of Immunology, vol. 170, no. 1, pp. 132–138, 2003. View at Google Scholar
  26. S. Kanemitsu, K. Ihara, A. Saifddin et al., “A functional polymorphism in Fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus,” Journal of Rheumatology, vol. 29, no. 6, pp. 1183–1188, 2002. View at Google Scholar
  27. H. Shen, Y. Zheng, E. M. Sturgis, M. R. Spitz, and Q. Wei, “p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study,” Cancer Letters, vol. 183, no. 2, pp. 123–130, 2002. View at Publisher · View at Google Scholar
  28. A. Hazra, R. M. Chamberlain, H. B. Grossman, Y. Zhu, M. R. Spitz, and X. Wu, “Death receptor 4 and bladder cancer risk,” Cancer Research, vol. 63, no. 6, pp. 1157–1159, 2003. View at Google Scholar
  29. T. Sun, X. Miao, X. Zhang, W. Tan, P. Xiong, and D. Lin, “Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma,” Journal of the National Cancer Institute, vol. 96, no. 13, pp. 1030–1036, 2004. View at Google Scholar
  30. B. J. Stuck, M. A. Pani, F. Besrour et al., “Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease,” Human Immunology, vol. 64, no. 2, pp. 285–289, 2003. View at Publisher · View at Google Scholar
  31. X. Ke, A. Collins, and S. Ye, “PIRA PCR designer for restriction analysis of single nucleotide polymorphisms,” Bioinformatics, vol. 17, no. 9, pp. 838–839, 2001. View at Publisher · View at Google Scholar
  32. L.-E. Wang, L. Cheng, M. R. Spitz, and Q. Wei, “Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer,” Lung Cancer, vol. 42, no. 1, pp. 1–8, 2003. View at Publisher · View at Google Scholar
  33. M. Stephens and P. Donnelly, “A comparison of Bayesian methods for Haplotype reconstruction from population Genotype data,” American Journal of Human Genetics, vol. 73, no. 5, pp. 1162–1169, 2003. View at Publisher · View at Google Scholar
  34. V. M. Salas and S. W. Burchiel, “Apoptosis in Daudi human B cells in response to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol,” Toxicology and Applied Pharmacology, vol. 151, no. 2, pp. 367–376, 1998. View at Publisher · View at Google Scholar
  35. S. J. Korsmeyer, “Regulators of cell death,” Trends in Genetics, vol. 11, no. 3, pp. 101–105, 1995. View at Publisher · View at Google Scholar
  36. J. C. Reed, “Bcl-2 and the regulation of programmed cell death,” Journal of Cell Biology, vol. 124, no. 1-2, pp. 1–6, 1994. View at Publisher · View at Google Scholar
  37. Q.-L. Lu, P. Abel, C. S. Foster, and E.-N. Lalani, “bcl-2: role in epithelial differentiation and oncogenesis,” Human Pathology, vol. 27, no. 2, pp. 102–110, 1996. View at Publisher · View at Google Scholar
  38. L. Kaklamanis, A. Savage, N. Mortensen et al., “Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia,” Journal of Pathology, vol. 179, no. 1, pp. 10–14, 1996. View at Publisher · View at Google Scholar
  39. J. C. Reed, “Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies,” Seminars in Hematology, vol. 34, no. 4, supplement 5, pp. 9–19, 1997. View at Google Scholar
  40. L. R. Kidd, A. Coulibaly, T. M. Templeton et al., “Germline BCL-2 sequence variants and inherited predisposition to prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 9, no. 3, pp. 284–292, 2006. View at Publisher · View at Google Scholar
  41. P. Dumont, J. I.-J. Leu, A. C. Della Pietra III, D. L. George, and M. Murphy, “The codon 72 polymorphic variants of p53 have markedly different apoptotic potential,” Nature Genetics, vol. 33, no. 3, pp. 357–365, 2003. View at Publisher · View at Google Scholar
  42. A. Osorio, B. Martínez-Delgado, M. Pollán et al., “A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers,” Human Mutation, vol. 27, no. 3, pp. 242–248, 2006. View at Publisher · View at Google Scholar
  43. M. Thomas, A. Kalita, S. Labrecque, D. Pim, L. Banks, and G. Matlashewski, “Two polymorphic variants of wild-type p53 differ biochemically and biologically,” Molecular and Cellular Biology, vol. 19, no. 2, pp. 1092–1100, 1999. View at Google Scholar
  44. A. Schmitz, J. Bayer, N. Dechamps, L. Goldin, and G. Thomas, “Heritability of susceptibility to ionizing radiation-induced apoptosis of human lymphocyte subpopulations,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 4, pp. 1169–1177, 2007. View at Publisher · View at Google Scholar